NANOBIOTIX joins the CAC Mid 60 and SBF 120 indices

NANOBIOTIX, a French biotechnology company, has announced its inclusion in the CAC Mid 60 and SBF 120 indices of Euronext Paris. This decision, made during the annual review of the indices by the Scientific Council of Indices, will take effect on December 19, 2025, after market close. These indices are key benchmarks for mid-sized and large companies listed in France. The inclusion of NANOBIOTIX could increase its visibility among institutional investors and strengthen its presence in European markets.

Laurent Levy, co-founder and chairman of the board of NANOBIOTIX, expressed his honor at this integration. He emphasized that it reflects the continued confidence of the financial markets in the company's strategy and the potential of its nanotherapeutic solutions. This step marks a turning point for NANOBIOTIX, which aims to revolutionize the treatment of diseases through physics-based technologies.